Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


Business Summary
Gyroscope Therapeutics Holdings plc, formerly Gyroscope Therapeutics Holdings Limited, is a clinical-stage gene therapy company. The Company develop gene therapy beyond rare diseases. It offers therapies to treat diseases of the eye that cause vision loss and blindness. The Company’s investigational gene therapy, GT005, is in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a cause of blindness. The Company develops a pipeline of recombinant adeno-associated virus (rAAV), vector-based gene therapy candidates targeting genetic variants in the pathway to be key drivers of AMD. Its gene therapies are designed as one-time treatments. The Company’s lead programs, GT005 and GT011, focus on two key targets such as Complement Factor I (CFI) and factor H like-1 (FHL1), a variant of Complement Factor H (CFH). Its gene therapy, GT005, is designed to restore balance to a system by production of CFI, a regulatory protein.
Sales per Business
Clinical - Stage Gene Therapy0.8691%
USD in Million
Sales per region
United States0.6063.7%
United Kingdom0.2627.3%
USD in Million
Name Title Age Since
Khurem Farooq Chief Executive Officer & Director 53 2019
Jessica Stitt Chief Financial Officer 43 2021
Jane Hughes, Dr. Chief Scientific Officer 46 2019
Ian Pitfield, Dr. Senior Vice President-Technical Operations 54 2020
Nadia Waheed, Dr. Chief Medical Officer 43 2020
Edward Lang Chief Business Officer 40 2019
Members of the board
Name Title Age Since
Christopher John Hollowood, Dr. Chairman 46 2016
Khurem Farooq Chief Executive Officer & Director 53 2019
Sean Bohen, Dr. Non-Executive Director 54 2020
Ian T. Clark Non-Executive Director 60 2019
Jennifer E. Cook Non-Executive Director 54 2020
David A. Fellows Non-Executive Director 63 2020
Renée Galá Non-Executive Director 48 2020
Wouter Joustra Non-Executive Director - 2021
Maha Katabi, Dr. Non-Executive Director 46 2021
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 29,229,659 0 0.0% 0 0.0% 49.5%
Stock B 1 29,229,659 28,937,362 99.0% 0 0.0%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gyroscope Therapeutics Holdings plc